Table 2 Univariate and multivariate Cox regression analysis for 6-year biochemical failure in IR patients treated with RT alone
From: Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
Characteristic | Covariate type | Number at risk | Cumulative probability of biochemical failure | Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
HR | P | 95% C.I. | HR | P | 95% C.I. | ||||||
Lower | Upper | Lower | Upper | ||||||||
Age ≤ 70 years | Categorical | 56 | 17.9% | 3.32 | 0.018 | 1.226 | 8.464 | 3.06 | 0.025 | 1.153 | 8.138 |
Pretreatment PSA (ng/mL) | Continuous | 177 | 1.03 | 0.684 | 0.899 | 1.176 | |||||
Gleason score | Categorical | 177 | |||||||||
5 or 6 | 35 | 5.7% | 1 | reference | |||||||
7 (3 + 4) | 93 | 6.5% | 1.16 | 0.852 | 0.235 | 5.772 | 1.42 | 0.667 | 0.285 | 7.128 | |
7 (4 + 3) | 49 | 18.4% | 3.16 | 0.141 | 0.685 | 14.656 | 3.32 | 0.125 | 0.717 | 15.383 | |
T- stage T2b to T2c | Categorical | 61 | 11.5% | 1.73 | 0.280 | 0.641 | 4.664 | ||||
No. IR risk factors | Categorical | 177 | |||||||||
1 | 115 | 8.7% | 1 | reference | |||||||
2 | 55 | 10.9% | 1.76 | 0.278 | 0.635 | 4.856 | |||||
3 | 7 | 14.3% | 2.87 | 0.319 | 0.361 | 22.750 | |||||
Positive biopsy cores (%) | Continuous | 154 | 1 | 0.917 | 0.981 | 1.022 | |||||
Charlson comorbidity index | Categorical | 162 | |||||||||
2 | 69 | 11.6% | 1 | reference | |||||||
3 | 27 | 0% | 0.00 | 0.977 | 0.000 | 0.000 | |||||
≥4 | 49 | 10.9% | 0.72 | 0.836 | 0.309 | 2.261 | |||||